Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful ...
Ragnhild Langli (70) is the first person in Norway to receive personalized chemotherapy for bowel cancer. She is ...
Speaking at a hospice in Tunbridge Wells, she said: "I don't want to cloud her memory of me as just poorly." Beth added: "I ...
The Dawson's Creek alum, 48, was diagnosed with stage 3 colorectal cancer in 2023 and has been selling off merchandise from ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment. ...
A new AI tool is revolutionizing cancer treatment decisions by analyzing tissue images to predict tumor aggressiveness. This ...
Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...
In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the ...
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback